Better Options Stop sulfonylureas once ESKD develops
BPI Labs carries a March 2025 FDA warning letter with no posted response, a follow-up FMD-145 letter from July 2025, an active FDA do-not-use alert on its epinephrine nasal product, and a recent pause on compounded GLP-1s
Los efectos secundarios ms comunes son nuseas, diarrea, vmitos, estreimiento, dolor abdominal, dolor de cabeza, fatiga, dispepsia, mareos, distensin abdominal, eructos, hipoglucemia en personas con diabetes tipo 2, flatulencia, gastroenteritis y enfermedad por reflujo gastroesofgico
In patients with severe gastrointestinal motility disorders, such as gastroparesis, this pharmacologic effect can intensify symptoms